ATE494904T1 - Verbindungen und verfahren zur erhöhung der neurogenese - Google Patents

Verbindungen und verfahren zur erhöhung der neurogenese

Info

Publication number
ATE494904T1
ATE494904T1 AT03772495T AT03772495T ATE494904T1 AT E494904 T1 ATE494904 T1 AT E494904T1 AT 03772495 T AT03772495 T AT 03772495T AT 03772495 T AT03772495 T AT 03772495T AT E494904 T1 ATE494904 T1 AT E494904T1
Authority
AT
Austria
Prior art keywords
methods
agents
compounds
increase neurogenesis
neurogenesis
Prior art date
Application number
AT03772495T
Other languages
English (en)
Inventor
Goeran Bertilsson
Rikard Erlandsson
Jonas Frisen
Anders Haegerstrand
Jessica Heidrich
Kristina Hellstroem
Johan Haeggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna Fraemme
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Roennholm
Olof Zachrisson
Lilian Wikstroem
Original Assignee
Neuronova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494904(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuronova Ab filed Critical Neuronova Ab
Application granted granted Critical
Publication of ATE494904T1 publication Critical patent/ATE494904T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03772495T 2002-11-20 2003-11-20 Verbindungen und verfahren zur erhöhung der neurogenese ATE494904T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42791202P 2002-11-20 2002-11-20
PCT/IB2003/005311 WO2004045592A2 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis

Publications (1)

Publication Number Publication Date
ATE494904T1 true ATE494904T1 (de) 2011-01-15

Family

ID=32326612

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03772495T ATE494904T1 (de) 2002-11-20 2003-11-20 Verbindungen und verfahren zur erhöhung der neurogenese

Country Status (13)

Country Link
US (1) US20050009847A1 (de)
EP (1) EP1583541B1 (de)
JP (2) JP5420813B2 (de)
AT (1) ATE494904T1 (de)
AU (1) AU2003280117B2 (de)
CA (1) CA2506850C (de)
CY (1) CY1111386T1 (de)
DE (1) DE60335743D1 (de)
DK (1) DK1583541T3 (de)
ES (1) ES2359720T3 (de)
PT (1) PT1583541E (de)
SI (1) SI1583541T1 (de)
WO (1) WO2004045592A2 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691145B2 (en) * 1999-10-22 2010-04-06 Facet Solutions, Inc. Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces
EP1423509A2 (de) * 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differenzierung von neuralen stammzellen und therapeutische anwendung
US7393830B2 (en) * 2001-09-14 2008-07-01 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
EP1546198A1 (de) * 2002-07-31 2005-06-29 Stem Cell Therapeutics Inc. Verfahren zur verbesserung der proliferation, der differenzierung und des berlebens von neuralen stammzellen unter verwendung von pituitary adenylate cyclase activating polypeptide (pacap)
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
EP1750752A2 (de) * 2003-11-20 2007-02-14 Neuronova AB Verbindungen und verfahren zur steigerung der neurogenese
JP4990634B2 (ja) * 2004-02-13 2012-08-01 ステム セル セラピューティクス コーポレイション 神経幹細胞の増殖および神経発生のための黄体化ホルモン（ＬＨ）、および絨毛性ゴナドトロピン（ｈＣＧ）の使用
WO2005116065A1 (en) 2004-05-24 2005-12-08 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy
US8475764B2 (en) 2004-05-24 2013-07-02 Institut De Cardiologie De Montreal Labelled adrenomedullin derivatives and their use for imaging and therapy
EP1619251A1 (de) 2004-07-22 2006-01-25 Prosensa B.V. Ein mRNA Spleisvariant des Doublecortin-ähnlichen Kinasegens und dessen Anwendung in Krebsdiagnosis und Krebstherapie
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009509943A (ja) 2005-09-27 2009-03-12 ステム セル セラピューティクス コーポレイション プロラクチンにより制御される乏突起膠細胞前駆体細胞の増殖
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP5050195B2 (ja) * 2006-02-14 2012-10-17 国立大学法人 岡山大学 神経細胞分化誘導剤
JP5424291B2 (ja) * 2006-03-03 2014-02-26 独立行政法人国立循環器病研究センター 骨髄細胞の動員剤および動員方法
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
CA2644116A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
KR100838013B1 (ko) * 2006-06-07 2008-06-12 제일약품주식회사 인간배아줄기세포로부터 단계적 선별법을 통해 고수율로신경전구세포, 신경세포 및 기능성 도파민신경세포를생성하는 방법
EP2068872A1 (de) * 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
EP2066355A2 (de) * 2006-09-19 2009-06-10 Braincells, Inc. Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008071438A2 (en) * 2006-12-14 2008-06-19 Neuronova Ab Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
EP2125017A2 (de) * 2007-01-11 2009-12-02 Braincells, Inc. Neurogenese-modulation durch verwendung von modafinil
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2008138141A1 (en) * 2007-05-11 2008-11-20 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
WO2009017655A2 (en) * 2007-07-27 2009-02-05 Immuneregen Biosciences, Inc. Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
JP2010539057A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのヒト膵臓ポリペプチドの使用
WO2009040020A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Amylin as a therapeutic agent
WO2009033746A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009033809A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
ES2375924T3 (es) * 2008-01-18 2012-03-07 Centre National De La Recherche Scientifique - Cnrs Agonistas beta-2 adrenérgicos para su utilización en el tratamiento de la alodinia neurop�?tica crónica.
FR2926464B1 (fr) * 2008-01-18 2012-01-20 Centre Nat Rech Scient Composes utilisables pour le traitement de douleurs neuropathiques
WO2009123877A1 (en) * 2008-03-21 2009-10-08 Braincells, Inc. A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
JPWO2009136587A1 (ja) * 2008-05-08 2011-09-08 株式会社カネカ 抗疲労組成物
WO2010019450A2 (en) * 2008-08-09 2010-02-18 Nyles Bauer Synergizing active compounds for treating inflammation and other conditions
GB0815315D0 (en) * 2008-08-21 2008-09-24 Univ Leiden Organ protection
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010106494A1 (en) 2009-03-20 2010-09-23 H.L. Hall & Sons Limited Use of pharmaceutical compositions containing mesembrenone
WO2010106495A1 (en) 2009-03-20 2010-09-23 H.L. Hall & Sons Limited Sceletium extract and uses thereof
JP5498571B2 (ja) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
WO2010132605A1 (en) * 2009-05-13 2010-11-18 Protein Delivery Solutions, Llc Pharmaceutical system for trans-membrane delivery
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
ES2688072T3 (es) * 2010-05-11 2018-10-30 Mallinckrodt Ard Ip Limited ACTH para el tratamiento de la esclerosis lateral amiotrófica
PT2582368T (pt) * 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
HUE029393T2 (en) 2010-08-31 2017-03-28 Bionure Farma S L Neurotrophin receptor agonists and their use as medicaments
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20140221319A1 (en) * 2011-06-29 2014-08-07 Mayo Foundation For Medical Education And Research Small Molecule CD38 Inhibitors and Methods of Using Same
CA2847247C (en) 2011-08-29 2019-10-15 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
ES2825101T3 (es) * 2013-07-08 2021-05-14 Univ Midwestern Composiciones y métodos para el tratamiento de trastornos neuropsiquiátricos usando un agonista del receptor de la endotelina B
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CA2987033C (en) * 2015-06-22 2023-11-28 Nestec S.A. Compositions and methods for enhancing neurogenesis in animals
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CA3019089A1 (en) * 2016-03-31 2017-10-05 Ajinomoto Co., Inc. Medium for neural stem cells enhancing neural differentiation ability
JP7029707B2 (ja) * 2016-10-17 2022-03-04 国立大学法人 熊本大学 ｃＡＭＰの増加をメカニズムとする有機酸血症における神経障害治療薬剤
EP3658167A1 (de) 2017-07-26 2020-06-03 HG&H Pharmaceuticals (Pty) Limited Mesembrenol und / oder mesembranol zur prophylaxe und behandlung von patienten mit epilepsie und assoziierten krankheiten
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
KR102026156B1 (ko) * 2018-03-16 2019-09-27 (주)메디노 신경줄기세포의 신경분화 방법
EP3810126A4 (de) * 2018-06-21 2022-04-27 Board of Regents of the Nevada System of Higher Education, on Behalf of the University of Nevada, Reno Krankheitsmodifizierende verfahren zur behandlung neurodegenerativer erkrankungen unter verwendung nootroper mittel
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
WO2021011878A1 (en) * 2019-07-18 2021-01-21 Venturis Therapeutics, Inc. Method of treating parkinson's disease
EP4069109A4 (de) * 2019-12-05 2024-02-21 The Methodist Hospital System Stabilisierte arzneimittelformulierungen und verfahren zum laden von arzneimittelabgabeimplantaten
CN115996743A (zh) * 2020-07-08 2023-04-21 基立福环球运营有限公司 具有神经再生性应用的组合物
JP2022104448A (ja) * 2020-12-28 2022-07-08 純一 今村 認知症治療薬
CN113121641B (zh) * 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
US20220323547A1 (en) * 2021-04-13 2022-10-13 Therapeutic Solutions International, Inc. Amelioration and Treatment of Opioid Addiction
CN115869459B (zh) * 2021-09-27 2024-06-21 广州图微科创生物科技有限公司 促伤口愈合的多肽水凝胶及其制备方法与应用
CN115887619B (zh) * 2021-09-30 2024-03-26 四川大学 中脑星形胶质细胞源性神经营养因子的用途及药物组合物
WO2024030977A2 (en) * 2022-08-03 2024-02-08 Sightstream Biotherapeutics, Inc. Novel melanocortin analogs
WO2024142211A1 (ja) * 2022-12-27 2024-07-04 純一 今村 認知症治療薬
US12194037B2 (en) * 2023-01-06 2025-01-14 Microneb Tech Holdings, Inc. Apparatus, methods, and systems for providing pharmaceutical compositions and administering medications to patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016437A1 (en) * 1993-12-17 1995-06-22 Micro-Pak, Inc. Method of transmitting a biologically active material to a cell
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
US6284539B1 (en) * 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
US7741310B2 (en) * 2000-05-05 2010-06-22 Research Foundation Of The City University Of New York Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20040247571A1 (en) * 2001-04-23 2004-12-09 Xia Meijer Neural cells expressing tyrosine hydroxylase

Also Published As

Publication number Publication date
JP2006514630A (ja) 2006-05-11
JP2010195841A (ja) 2010-09-09
DK1583541T3 (da) 2011-04-11
WO2004045592A3 (en) 2004-11-04
HK1091112A1 (en) 2007-01-12
PT1583541E (pt) 2011-04-06
CA2506850A1 (en) 2004-06-03
DE60335743D1 (de) 2011-02-24
EP1583541A2 (de) 2005-10-12
CY1111386T1 (el) 2015-08-05
AU2003280117B2 (en) 2009-09-10
JP5421194B2 (ja) 2014-02-19
CA2506850C (en) 2014-05-13
US20050009847A1 (en) 2005-01-13
ES2359720T3 (es) 2011-05-26
AU2003280117A1 (en) 2004-06-15
JP5420813B2 (ja) 2014-02-19
SI1583541T1 (sl) 2011-08-31
EP1583541B1 (de) 2011-01-12
WO2004045592A2 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
ATE554108T1 (de) Verfahren bezüglich ldcam und crtam
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200500856A1 (ru) Новые химические соединения
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
BR0310092A (pt) Combinação de compostos orgânicos
NO20034056D0 (no) Proliferative sykdommer
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
MXPA05011233A (es) Vectores peptidicos.
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
BRPI0510947A (pt) tratamento de doença respiratória
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
ATE416756T1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
DE60323533D1 (de) Methode zur stimulierung von haarwuchs auf der basis von benzopyranen
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1583541

Country of ref document: EP